Amy Lichtenfeld, MD
Internal Medicine · New York, NYNPI 1851356141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 822 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 822 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Sanofi$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Novartis$1K
- plus $6K from 36 others
Across 2 payments — averaging $85.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$172
What the payments were for
- Food & beverage$17,060100%
- Education$520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$17,112 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fasenra PenBenralizumab | 13 | $72,012 |
| FarxigaDapagliflozin Propanediol | 13 | $7,617 |
| EliquisApixaban | 12 | $7,177 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,352 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $3,441 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,311 |
| Epinephrine | 12 | $2,055 |
| Montelukast Sodium | 87 | $842 |
| Azelastine Hcl | 27 | $765 |
| Ipratropium Bromide | 18 | $656 |
| Levocetirizine Dihydrochloride | 26 | $632 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $570 |
| Omeprazole | 21 | $515 |
| Fluticasone Propionate | 31 | $474 |
| Levothyroxine Sodium | 31 | $465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $3,183 | $7,61713 claims |
| PfizerEliquis | $327 | $7,17712 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $223 | $3,44112 claims |
| Hikma Pharmaceuticals USAEpinephrine | $73 | $2,05512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.